S
edation and analgesia are important components of the management of intubated, mechanically ventilated patients. Patient comfort is a central goal, 1 but is especially challenging after severe injury. In addition, pain and anxiety may be associated with intubation, invasive bedside procedures performed for monitoring or management, and the intensive care environment. In the trauma patient, these issues are complicated by pain associated with operative incisions, fractures, and soft tissue injury. The prior use of excessive alcohol or illicit drugs in the trauma population adds additional complexity to management. Head injury management often requires a very meticulous balancing of medication to enable patient comfort without clouding neurologic assessment. Patient comfort may be further complicated by delirium. This is a syndrome of fluctuating consciousness, with reduced attention and impaired cognitive function. Its multifactorial origins may include the metabolic and physiologic derangements of critical illness as well as acute brain injury. Delirium is associated with prolongation of hospital stay and increased mortality. [2] [3] [4] Overuse of medication for sedation and analgesia may have adverse effects, including hemodynamic instability, prolongation of mechanical ventilation, other complications associated with sustained bed rest and immobility, and may facilitate the development of later posttraumatic stress disorder. 5, 6 Thus, appropriate use of drugs for the management of sedation and analgesia has implications that extend beyond patient comfort.
The recognition of pain, anxiety, and delirium as independent contributors to patient distress enables a more appropriately focused management strategy that targets these symptoms individually with appropriate medication. Symptoms should be rapidly controlled, to avoid a cycle of inadequate dosing and escalating need. Pharmacotherapeutic intervention should be directed to minimize adverse effects while accomplishing this goal. It is also important to recognize that sedation and analgesia are closely related; that is, anxiety reduces the pain threshold, and pain control may reduce anxiety. This concept justifies the use of multiple drugs for symptom management. Narcotics are primarily used for pain management in the intensive care unit (ICU), whereas benzodiazepenes and propofol are used for anxiety control, and antipsychotic medications are used for other agitation and delirium. 7, 8 A regular and systematic assessment of the intubated patient for signs of distress, using a consistent evaluation tool, should minimize the amount of sedation necessary and allow the patient to recover from the sedated state more promptly.
Inflammation and the Host Response to Injury is a largescale collaborative research project funded in September 2001 by the National Institute of General Medical Sciences, National Institutes of Health. The purpose of this study is fourfold: (1) to develop a large database with baseline patient characteristics and defined outcomes pertaining to the host immunoinflammatory response after injury; (2) to identify gene-expression patterns in circulating leukocytes and tissue samples to classify the response to injury; (3) to determine the relationships among genes and gene clusters, and how they are expressed over time after injury; and (4) to determine the relevance of murine models of injury to human disease through comparison of the immunoinflammatory response. 9 The clinical components of this project are managed through the Patient Oriented Research Core (PORC), whose members comprise the named authors of this article.
Standard operating procedures for clinical care (SOP) were developed by the participating investigators to minimize clinical variation and establish uniform practices to enhance the estimations of the host inflammatory response to injury. The SOPs were developed because of an absence of any such protocols in print to use in this patient population. The PORC meets quarterly, and communicates between meetings electronically. After review of the medical literature, the principle author presents an analysis of the available data to the PORC investigators for discussion and interpretation modified by clinical expertise. The principle author prepares the guideline, which is again reviewed by the entire PORC, and approved after modification.
For the present inquiry, standard search engines (PubMed and MedLine) for comprehensive data acquisition were queried for references to sedation and analgesia in mechanical ventilation, which were used to supplement more immediately accessible literature in this matter. After internal review by the PORC investigators, this SOP was created based on the best available external evidence.
The Inflammation and the Host Response to Injury Investigators will use this SOP, and others prepared by the PORC, to eliminate background variations in clinical interventions. The product also sets a standard for trials directly focused on the SOP criteria. The authors recognize that these are not static documents and will modify SOP as new evidence-based data directs or new approaches to care have demonstrated benefit.
The primary purpose of this guideline is to provide physician and nursing staffs with a strategy for the pharmacologic management of pain, anxiety, and delirium that may affect intubated patients.
The Protocol has as its principal goals the following: • To ensure that sedation level is evaluated using an objective-scoring tool; • To provide guidelines for medication use that will lead to prompt and adequate control of pain, agitation, and delirium, without causing oversedation; and • To provide an algorithm for medication management that enables more timely responsiveness to changes in patients' medication requirements.
Protocol Rationale

Objective Assessment of Sedation Level
Ideally patients requiring mechanical ventilation should be pain-free and calm. Pain, agitation, and delirium may be multifactorial, but the recognition of these distinct conditions is central to effective pharmacologic control of symptoms. The management of sedation requires that a clearly defined goal of therapy be established. Precise communication between providers is necessary to maintain consistency in symptom management. The balance of adequate versus inadequate medication depends on an objective serial evaluation of a patient's response to therapy in the context of the stated goal. Recent clinical practice guidelines for sedation and analgesia recommend the use of a sedation scale for this purpose. 10 Although several scales have been developed, the Richmond Agitation-Sedation Scale (RASS) is used in these guidelines. 11 This simple system assigns a score between 4 (combative) and Ϫ5 (unresponsive). A score of zero indicates that the patient is alert and calm. The RASS is notable for ease of use, excellent inter-rater reliability, and greater discriminatory capacity than other commonly used scales.
12
Management of Sedation and Analgesia by Algorithm
The status of critically ill patients changes frequently and so, too, do their requirements for sedation and analgesia. The ability to respond promptly to dynamic changes in medication requirement must be a central component of a program to manage these effectively. Sedation management by algorithm has been studied and is clearly advantageous. In a prospective, randomized, controlled study, sedation management of 321 mechanically ventilated patients according to a nurseimplemented protocol was associated with significantly shorter duration of ventilation, decreased rate of tracheostomy, and improved ICU and hospital length of stay. 13 This study was notable for using a protocol that used physician input to establish a target goal of sedation, and then empowered the nursing staff to adjust analgesia and sedation medication in a more timely fashion to achieve this endpoint.
Intermittent Versus Continuous Sedation
Controversy exists over whether continuous or intermittent sedation is best for critically ill patients. In one prospec-
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14 The same authors affirmed the relationship of continuous sedation and duration of ventilation in a subsequent randomized, controlled trial, although this was not the primary purpose of the trial. 13 This evidence must be balanced against concerns that intermittent dosing may undermedicate patients in the short term and lead to greater cumulative dosing in the long term.
A recent, open-label, randomized trial compared length of mechanical ventilation in patients receiving continuous propofol versus intermittent lorazapam, incorporating a daily sedation interruption. 15 Median ventilator days were significantly reduced in patients receiving continuous propofol, suggesting that the choice of sedating drug may be as important as the mode of delivery. Similar consensus pain management guidelines have not entirely resolved this issue, with recommendations that analgesia should be administered either continuously or on a scheduled intermittent basis, with supplemental bolus doses as needed. 16 Acknowledging the lack of definitive data to direct practice clearly, but with focus on the principle of prompt symptom control, we propose the initial approach to sedation and analgesia management should include an intermittent dose strategy. Continuous infusions should be reserved for those patients in whom the target sedation level cannot be achieved within a timely manner.
Interruption of Sedation and Analgesia
Because "adequate" sedation is often equated with unresponsiveness, the possibility that sedation itself contributes to prolonged mechanical ventilation and its attendant complications must be considered. A randomized, controlled trial of daily interruption of continuous sedation has been performed to assess the affect on length of mechanical ventilation. 17 Continuous sedative and analgesic infusions were stopped until the patient was awake or uncomfortable and in need of resumed medication. In the cohort in which sedation was interrupted on a daily basis, the duration of mechanical ventilation was significantly reduced (median duration 2.4 days less than standard care), as were the length of ICU stay and total drug used. The rate of unplanned extubation was not increased. Interrupting medication may be inappropriate for patients who require sustained deep sedation for medical management (e.g., adult respiratory distress syndrome [ARDS], shock, or open chest or abdomen). For other patients, however, the guideline presented here incorporates the concept of the daily sedation interruption by setting the target sedation level to a RASS of 0 to -2, which approximates the criteria for "awake" described in the trial above.
Protocol Summary
A. The responsible physician should make an initial determination of the goal level of sedation for each patient, defined by the RASS score. This goal should be reassessed as often as clinically appropriate, but no less than daily. B. The patient should be assessed regularly for signs or symptoms of pain, anxiety, or delirium. The patient's RASS score should be assessed every 15 minutes until symptoms are controlled within the target range, and then every 4 hours thereafter. C. Fentanyl is the drug of choice for pain, chosen for its relative lack of histamine release and greater hemodynamic stability. (Morphine is also widely used for analgesia. Its use has been associated with histamine-related hemodynamic change and impaired clearance in patients with renal failure. Nevertheless, provider familiarity and experience may, in some centers, be grounds for its preferential use.) Propofol may be used for anxiety if the expected duration of sedation is less than 48 hours and if frequent neurologic assessments are necessary. Alternatively, or if the duration of sedation will exceed 48 hours, lorazepam should be used to control anxiety. Lorazepam offers significant cost savings over propofol and avoids potential complications of hyperlipidemia and, rarely, cardiac decompensation. Because of the speed with which propofol is cleared when discontinued, and the potential for faster weaning and extubation, it may be cost effective to use propofol when the anticipated duration of ventilation is short. Haloperidol is used when pharmacologic control of agitation from delirium is required. This guideline does not attempt to prevent, minimize, or diagnose delirium but rather to control the agitation that established delirium may produce. Part of delirium management should be to identify and control the inciting cause, and in some cases, sedation and analgesia may contribute to this problem. Delirium severity scales have been described to help in this assessment. A recent retrospective, observational analysis in patients mechanically ventilated for more than 48 hours found a significant reduction in hospital mortality in those patients who received haloperidol within 2 days of initiation of mechanical ventilation. 18 The explanation of this finding remains speculative, and these results have not been reassessed in a randomized, prospective, placebo-controlled trial. D. Initial dosing should be intermittent. If adequate symptom control cannot be achieved with the described regimen of bolus dosing, a continuous infusion may be used for pain and anxiety control, titrated to the lowest dose necessary to achieve the target RASS score.
Guideline Details
1. A target level of sedation will be established based on the patient's condition and expected duration of mechanical ventilation (Fig. 1) . Unless medically contraindicated, the optimal level is that at which the patient is alert, not agitated, and able to maintain brief contact and follow simple instructions (RASS 0 to Ϫ2; Fig. 2 The Journal of TRAUMA Injury, Infection, and Critical Care the infusion by 10 g/kg/min every 15 minutes to a maximum of 100 g/kg/min. Consider the possible contribution of pain and delirium to the appearance of agitation. 5. Antipsychotic for delirium: Bolus haloperidol, 2 mg to 10 mg intravenously every 1 hour as needed. If the goal is not met in 6 hours, begin scheduled doses of 5 mg intravenously every 6 hours and continue bolus doses. 6. Unless medically contraindicated in patients sedated to a RASS score of Ϫ3 to Ϫ5, sedation should be interrupted daily until the patient is awake (establishes brief eye contact or follows simple instructions) or until the patient becomes agitated or uncomfortable. 
